Literature DB >> 27688314

Genotype-Dependent and -Independent Calcium Signaling Dysregulation in Human Hypertrophic Cardiomyopathy.

Adam S Helms1, Francisco J Alvarado2, Jaime Yob2, Vi T Tang2, Francis Pagani2, Mark W Russell2, Héctor H Valdivia2, Sharlene M Day2.   

Abstract

BACKGROUND: Aberrant calcium signaling may contribute to arrhythmias and adverse remodeling in hypertrophic cardiomyopathy (HCM). Mutations in sarcomere genes may distinctly alter calcium handling pathways.
METHODS: We analyzed gene expression, protein levels, and functional assays for calcium regulatory pathways in human HCM surgical samples with (n=25) and without (n=10) sarcomere mutations compared with control hearts (n=8).
RESULTS: Gene expression and protein levels for calsequestrin, L-type calcium channel, sodium-calcium exchanger, phospholamban, calcineurin, and calcium/calmodulin-dependent protein kinase type II (CaMKII) were similar in HCM samples compared with controls. CaMKII protein abundance was increased only in sarcomere-mutation HCM (P<0.001). The CaMKII target pT17-phospholamban was 5.5-fold increased only in sarcomere-mutation HCM (P=0.01), as was autophosphorylated CaMKII (P<0.01), suggestive of constitutive activation. Calcineurin (PPP3CB) mRNA was not increased, nor was RCAN1 mRNA level, indicating a lack of calcineurin activation. Furthermore, myocyte enhancer factor 2 and nuclear factor of activated T cell transcription factor activity was not increased in HCM, suggesting that calcineurin pathway activation is not an upstream cause of increased CAMKII protein abundance or activation. SERCA2A mRNA transcript levels were reduced in HCM regardless of genotype, as was sarcoplasmic endoplasmic reticular calcium ATPase 2/phospholamban protein ratio (45% reduced; P=0.03). 45Ca sarcoplasmic endoplasmic reticular calcium ATPaseuptake assay showed reduced uptake velocity in HCM regardless of genotype (P=0.01). The cardiac ryanodine receptor was not altered in transcript, protein, or phosphorylated (pS2808, pS2814) protein abundance, and [3H]ryanodine binding was not different in HCM, consistent with no major modification of the ryanodine receptor.
CONCLUSIONS: Human HCM demonstrates calcium mishandling through both genotype-specific and common pathways. Posttranslational activation of the CaMKII pathway is specific to sarcomere mutation-positive HCM, whereas sarcoplasmic endoplasmic reticular calcium ATPase 2 abundance and sarcoplasmic reticulum Ca uptake are depressed in both sarcomere mutation-positive and -negative HCM.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  calcium; calcium-calmodulin-dependent protein kinase type 2; cardiomyopathy, hypertrophic; genetics; sarcomeres; sarcoplasmic reticulum calcium-transporting ATPases

Mesh:

Substances:

Year:  2016        PMID: 27688314      PMCID: PMC5127749          DOI: 10.1161/CIRCULATIONAHA.115.020086

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

1.  Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy.

Authors:  Tetsuo Konno; Dan Chen; Libin Wang; Hiroko Wakimoto; Polakit Teekakirikul; Matthew Nayor; Masataka Kawana; Seda Eminaga; Joshua M Gorham; Kumar Pandya; Oliver Smithies; Francisco J Naya; Eric N Olson; J G Seidman; Christine E Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-05       Impact factor: 11.205

2.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

3.  Myofilament Ca sensitization increases cytosolic Ca binding affinity, alters intracellular Ca homeostasis, and causes pause-dependent Ca-triggered arrhythmia.

Authors:  Tilmann Schober; Sabine Huke; Raghav Venkataraman; Oleksiy Gryshchenko; Dmytro Kryshtal; Hyun Seok Hwang; Franz J Baudenbacher; Björn C Knollmann
Journal:  Circ Res       Date:  2012-05-29       Impact factor: 17.367

4.  Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice.

Authors:  Samantha P Harris; Christopher R Bartley; Timothy A Hacker; Kerry S McDonald; Pamela S Douglas; Marion L Greaser; Patricia A Powers; Richard L Moss
Journal:  Circ Res       Date:  2002-03-22       Impact factor: 17.367

5.  An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy.

Authors:  D Fatkin; B K McConnell; J O Mudd; C Semsarian; I G Moskowitz; F J Schoen; M Giewat; C E Seidman; J G Seidman
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

6.  Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.

Authors:  Raffaele Coppini; Cecilia Ferrantini; Lina Yao; Peidong Fan; Martina Del Lungo; Francesca Stillitano; Laura Sartiani; Benedetta Tosi; Silvia Suffredini; Chiara Tesi; Magdi Yacoub; Iacopo Olivotto; Luiz Belardinelli; Corrado Poggesi; Elisabetta Cerbai; Alessandro Mugelli
Journal:  Circulation       Date:  2012-12-27       Impact factor: 29.690

7.  Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy.

Authors:  Michelle S C Khoo; Jingdong Li; Madhu V Singh; Yingbo Yang; Prince Kannankeril; Yuejin Wu; Chad E Grueter; Xiaoqun Guan; Carmine V Oddis; Rong Zhang; Lisa Mendes; Gemin Ni; Ernest C Madu; Jinying Yang; Martha Bass; Rey J Gomez; Brian E Wadzinski; Eric N Olson; Roger J Colbran; Mark E Anderson
Journal:  Circulation       Date:  2006-09-18       Impact factor: 29.690

8.  Heterogeneity of ryanodine receptor dysfunction in a mouse model of catecholaminergic polymorphic ventricular tachycardia.

Authors:  Randall Loaiza; Nancy A Benkusky; Patricia P Powers; Timothy Hacker; Sami Noujaim; Michael J Ackerman; José Jalife; Héctor H Valdivia
Journal:  Circ Res       Date:  2012-11-14       Impact factor: 17.367

9.  Calsarcin-1 protects against angiotensin-II induced cardiac hypertrophy.

Authors:  Derk Frank; Christian Kuhn; Martin van Eickels; Doris Gehring; Christiane Hanselmann; Stefanie Lippl; Rainer Will; Hugo A Katus; Norbert Frey
Journal:  Circulation       Date:  2007-11-19       Impact factor: 29.690

10.  Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.

Authors:  Bodvaël Fraysse; Florian Weinberger; Sonya C Bardswell; Friederike Cuello; Nicolas Vignier; Birgit Geertz; Jutta Starbatty; Elisabeth Krämer; Catherine Coirault; Thomas Eschenhagen; Jonathan C Kentish; Metin Avkiran; Lucie Carrier
Journal:  J Mol Cell Cardiol       Date:  2012-03-23       Impact factor: 5.000

View more
  34 in total

1.  Gene therapy for inherited arrhythmias.

Authors:  Vassilios J Bezzerides; Maksymilian Prondzynski; Lucie Carrier; William T Pu
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

2.  Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy.

Authors:  Adam S Helms; Vi T Tang; Thomas S O'Leary; Sabrina Friedline; Mick Wauchope; Akul Arora; Aaron H Wasserman; Eric D Smith; Lap Man Lee; Xiaoquan W Wen; Jordan A Shavit; Allen P Liu; Michael J Previs; Sharlene M Day
Journal:  JCI Insight       Date:  2020-01-30

Review 3.  Research progress on the role of CaMKII in heart disease.

Authors:  Shi-Jun Jiang; Wei Wang
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

Review 4.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Ali J Marian; Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

5.  A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.

Authors:  Timon Seeger; Rajani Shrestha; Chi Keung Lam; Caressa Chen; Wesley L McKeithan; Edward Lau; Alexa Wnorowski; George McMullen; Matthew Greenhaw; Jaecheol Lee; Angelos Oikonomopoulos; Soah Lee; Huaxiao Yang; Mark Mercola; Matthew Wheeler; Euan A Ashley; Fan Yang; Ioannis Karakikes; Joseph C Wu
Journal:  Circulation       Date:  2019-02-05       Impact factor: 29.690

6.  Chronic Calmodulin-Kinase II Activation Drives Disease Progression in Mutation-Specific Hypertrophic Cardiomyopathy.

Authors:  Sarah J Lehman; Lauren Tal-Grinspan; Melissa L Lynn; Joshua Strom; Grace E Benitez; Mark E Anderson; Jil C Tardiff
Journal:  Circulation       Date:  2019-03-19       Impact factor: 29.690

Review 7.  Biophysical Derangements in Genetic Cardiomyopathies.

Authors:  Melissa L Lynn; Sarah J Lehman; Jil C Tardiff
Journal:  Heart Fail Clin       Date:  2018-04       Impact factor: 3.179

Review 8.  Morphomechanic phenotypic variability of sarcomeric cardiomyopathies: A multifactorial polygenic perspective.

Authors:  Ares Pasipoularides
Journal:  J Mol Cell Cardiol       Date:  2018-11-10       Impact factor: 5.000

9.  Genetic basis and molecular biology of cardiac arrhythmias in cardiomyopathies.

Authors:  Ali J Marian; Babken Asatryan; Xander H T Wehrens
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

10.  Calcium-calmodulin-dependent protein kinase mediates the intracellular signalling pathways of cardiac apoptosis in mice with impaired glucose tolerance.

Authors:  Marilen Federico; Enrique L Portiansky; Leandro Sommese; Francisco J Alvarado; Paula G Blanco; Carolina N Zanuzzi; John Dedman; Marcia Kaetzel; Xander H T Wehrens; Alicia Mattiazzi; Julieta Palomeque
Journal:  J Physiol       Date:  2017-03-02       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.